5 Best NASDAQ Stocks Under $5 to Buy Right Now

4. MannKind Corporation (NASDAQ:MNKD)

Number of Hedge Fund Holders: 39

MannKind Corporation (NASDAQ:MNKD) is one of the best NASDAQ stocks under $5 to buy right now. On May 6, MannKind reported total revenues of $90.2 million for Q1 2026, marking a 15% increase compared to Q1 2025. This growth was driven by $15.5 million in net sales from Furoscix and a 9% increase in Tyvaso DPI royalties from United Therapeutics, which offset a 20% drop in collaboration revenues. Operating costs grew, with R&D expenses climbing 56% to $17.2 million and SG&A expenses rising 116% to $54.1 million due to the acquisition of scPharma and commercial launch preparations.

On the regulatory front, MannKind is approaching two key FDA action dates. The PDUFA date for the Afrezza inhaled insulin pediatric indication is set for May 29, while the Furoscix ReadyFlow Autoinjector has a target PDUFA date of July 26. To support these potential commercial expansions, the company has already built out its launch infrastructure and aligned its field-based teams.

In its development pipeline, MannKind Corporation (NASDAQ:MNKD) completed enrollment for the Phase 1b trial of Nintedanib DPI (MNKD-201) for idiopathic pulmonary fibrosis (IPF), with a Phase 2 trial expected to enroll its first patient in Q2 2026. Additionally, the company expanded its collaboration with United Therapeutics for Ralinepag DPI (MNKD-1501), receiving a $5 million payment to accelerate its development. Formulation work also continues for Bumetanide DPI (MNKD-701) to treat edema associated with heart and kidney disease.

MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company focused on developing and commercializing innovative inhaled therapeutic products and devices for those living with endocrine and orphan lung diseases.

1281292 - 1759070 - 1